Abatacept - Biologic Drug Details

Summary for abatacept

Tradenames:	1
High Confidence Patents:	0
Applicants:	1
BLAs:	1
Suppliers: see list	1
Recent Clinical Trials:	See clinical trials for abatacept
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for abatacept

Recent Clinical Trials for abatacept

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
National Heart, Lung, and Blood Institute (NHLBI)	Phase 1/Phase 2
Dr. Reddy's Laboratories Limited	Phase 1
Idelberto Badell	Phase 1

See all abatacept clinical trials

Recent Litigation for abatacept

Identify key patents and potential future biosimilar entrants

District Court Litigation

Case Name	Date
Janssen Biotech, Inc. v. Amgen Inc.	2022-11-29
AMGEN INC. v. APOTEX INC.	2022-06-14
Pharmacyclics LLC v. Alvogen Pine Brook, LLC	2020-03-20

See all abatacept litigation

PTAB Litigation

Petitioner	Date
Crescendo Bioscience, Inc et al.	2017-04-12

See all abatacept litigation

Pharmacology for abatacept

Physiological Effect	Decreased Cytokine Activity
Established Pharmacologic Class	Selective T Cell Costimulation Modulator
Chemical Structure	Recombinant Fusion Proteins

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. General brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for abatacept Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for abatacept Derived from Company Disclosures

No patents found based on company disclosures

3) Low Certainty: US Patents for abatacept Derived from Patent Text Search

No patents found based on company disclosures

Market Dynamics and Financial Trajectory for the Biologic Drug: Abatacept

Market Overview

The market for abatacept, a biologic drug primarily used to treat rheumatoid arthritis (RA) and psoriatic arthritis (PsA), is experiencing steady growth driven by several key factors.

Market Growth and Forecast

The global abatacept market is projected to grow at a compound annual growth rate (CAGR) of 2.2% to 2.3% from 2024 to 2031. By 2031, the market is expected to reach approximately USD 6.8 billion, up from USD 5.4 billion in 2023[3][4].

Drivers of Market Growth

Several factors are driving the growth of the abatacept market:

Increasing Prevalence of Autoimmune Diseases

The rise in the number of people suffering from rheumatoid arthritis and psoriatic arthritis globally is a major driver. Increased awareness about these autoimmune diseases and the growing prevalence of obesity, which is linked to these conditions, further accelerate market growth[1].

Technological Advancements and Collaborations

Advancements in technology offering better therapies and increased collaborations among manufacturers to develop new drugs are significant drivers. The low risk associated with abatacept compared to other RA therapies also extends profitable opportunities to market players[1].

Healthcare Sector Expansion

The global expansion of the healthcare sector, particularly in regions like North America and Asia-Pacific, is boosting the demand for abatacept. The growth in healthcare expenditure and the increasing geriatric population also contribute to market growth[1].

Market Segmentation

The abatacept market is segmented based on several criteria:

Product Type

The market is segmented into prefilled syringes and vials. These formats cater to different patient needs and preferences, influencing market dynamics[1][3].

Applications

Abatacept is primarily used for treating rheumatoid arthritis and psoriatic arthritis, with other applications also being explored. The dominance of RA treatment drives a significant portion of the market[1][3].

End-Users

The market is segmented into hospitals, homecare, specialty clinics, ambulatory surgical centers, and others. The distribution across these end-users reflects the diverse treatment settings where abatacept is administered[1].

Distribution Channels

The drug is distributed through hospital pharmacies, retail pharmacies, and online pharmacies. The convenience and accessibility offered by these channels impact market growth[1].

Regional Analysis

North America currently dominates the abatacept market due to its well-developed healthcare sector. However, the Asia-Pacific region is expected to witness high growth during the forecast period due to its large population and increasing healthcare infrastructure[1].

Cost-Effectiveness and Economic Impact

Abatacept, while more expensive than traditional non-biologic disease-modifying antirheumatic drugs (DMARDs) like methotrexate (MTX), has been shown to be cost-effective in certain scenarios. Studies indicate that abatacept can yield additional quality-adjusted life years (QALYs) at an incremental cost that is often within acceptable thresholds. For example, over a 10-year period, abatacept was found to yield 1.2 additional QALYs per patient at an incremental cost of $51,426, making it a viable option for patients with moderately to severely active RA who have an inadequate response to MTX[2].

Competitive Landscape

The competitive landscape of the abatacept market is characterized by the presence of key players such as Bristol-Myers Squibb, the primary manufacturer of Orencia (abatacept). The market dynamics are influenced by factors such as buyers' bargaining power, suppliers' bargaining power, the threat of new entrants, the threat of substitutes, and the degree of competition. The report includes a Porter's Five Forces analysis to provide a comprehensive understanding of the market ecosystem[3].

Challenges and Constraints

Despite the growth drivers, the abatacept market faces several challenges:

Availability of Alternative Therapies

The presence of various classes of drugs such as anti-tumor necrosis factor therapies, IL-17 therapies, and anti-TNF biologics can obstruct market growth. These alternatives offer patients and healthcare providers multiple treatment options, potentially diverting demand away from abatacept[1].

Low Awareness

Low awareness among people about autoimmune diseases and the benefits of abatacept is a significant challenge. Increasing awareness and education campaigns are necessary to fully capitalize on the market potential[1].

Patient Epidemiology and Market Impact

Patient epidemiology plays a crucial role in the abatacept market. The prevalence, incidence, mortality, and adherence rates of RA and PsA directly impact market growth. Detailed market analysis for patient prognosis and treatment outcomes helps in creating robust forecasting models[1].

Key Takeaways

• The global abatacept market is expected to grow at a CAGR of 2.2% to 2.3% from 2024 to 2031.
• The market is driven by the increasing prevalence of autoimmune diseases, technological advancements, and the expansion of the healthcare sector.
• North America dominates the market, but Asia-Pacific is expected to show high growth.
• Abatacept is cost-effective in certain scenarios, offering additional QALYs at an acceptable incremental cost.
• The market faces challenges from alternative therapies and low awareness among patients.

FAQs

Q: What is the projected market size of the abatacept market by 2031?

A: The global abatacept market is expected to reach approximately USD 6.8 billion by 2031[3].

Q: What are the primary drivers of the abatacept market growth?

A: The primary drivers include the increasing prevalence of autoimmune diseases, technological advancements, and the expansion of the healthcare sector[1].

Q: How does the cost-effectiveness of abatacept compare to other RA therapies?

A: Abatacept is more expensive than traditional non-biologic DMARDs but has been shown to be cost-effective in certain scenarios, offering additional QALYs at an acceptable incremental cost[2].

Q: What are the main challenges facing the abatacept market?

A: The main challenges include the availability of alternative therapies and low awareness among patients about autoimmune diseases and the benefits of abatacept[1].

Q: Which region is expected to show high growth in the abatacept market during the forecast period?

A: The Asia-Pacific region is expected to show high growth due to its large population and increasing healthcare infrastructure[1].

Sources

1. Data Bridge Market Research: Global Abatacept Market - Industry Trends and Forecast to 2029.
2. Oxford University Press: Cost–effectiveness of abatacept in patients with moderately to severely active RA and inadequate response to MTX.
3. Market Research Intellect: Orencia Abatacept Drug Market Size, Trends and Projections.
4. Valuates Reports: Orencia (Abatacept) Drug - Market Size.

Last updated: 2024-12-17